| P50 | author | Uwe Wollina | Q49366112 |
| P2093 | author name string | T Graefe | |
| | K Karte | |
| P2860 | cites work | Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. | Q34749386 |
| | Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group | Q36138642 |
| | Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment | Q37997915 |
| | Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups | Q39714882 |
| | Classification of cutaneous lymphomas. | Q40680341 |
| | A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides | Q40768413 |
| | Photopheresis therapy for cutaneous T-cell lymphoma | Q40926085 |
| | Cutaneous T-cell lymphoma (mycosis fungoides) | Q40982252 |
| | Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers | Q41637147 |
| | Adriamycin therapy in advanced mycosis fungoides | Q41868714 |
| | Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes | Q44239742 |
| | A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas | Q46237651 |
| | Alteration of cytokine genes and bcl-2 expression following immunotherapy with intralesional IFN-gamma in a patient with tumor-stage mycosis fungoides | Q47990103 |
| | Histologic and immunophenotypic features prior to transformation in patients with transformed cutaneous T-cell lymphoma: is CD25 expression in skin biopsy samples predictive of large cell transformation in cutaneous T-cell lymphoma? | Q53436270 |
| | Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial | Q59289264 |
| | Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy | Q72112446 |
| | Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates | Q72239750 |
| | CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study | Q74082921 |
| | A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma | Q74608106 |
| | Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481) | Q77123006 |
| | Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma | Q77142057 |
| | Does the amount of an antitumor agent entrapped in liposomes influence its tissue distribution and cell uptake? | Q77674413 |
| | Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP | Q77917003 |
| P433 | issue | 1 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| P304 | page(s) | 40-46 | |
| P577 | publication date | 2000-01-01 | |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin | |
| P478 | volume | 42 | |